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INTRODUCTION
On July 17, 2006, the Foundation for Taxpayer and Consumer
Rights (FTCR) filed a request for reexamination of the three stem cell
patents owned by the Wisconsin Alumni Research Foundation (WARF)
through the Public Patent Foundation. The consumer groups argue that
2
the patents hinder the progression of research. The United States
Patent and Trademark Office (USPTO) granted the request in
September 2006. Such reexamination could result in narrowing or
canceling of some or all of the claims. This Comment will outline why
the USPTO should not invalidate or significantly narrow the patents.
Specifically, this Comment will explain that the patents should remain
valid. First, this Comment will outline what stem cells are and what the
patents at issue cover. This Comment will then briefly explain the
applicable law and policy considerations. Finally, this Comment
discusses why the patents should withstand their current challenge.
I. WHAT ARE STEM CELLS?
There is no single definition of what a stem cell is or what its
3
characteristics are. However, there are a number of properties the
scientific community agrees upon being innate to stem cells. Stem cells
4
are undifferentiated precursor cells to other cells of the body. They
have the ability to propagate themselves, through proliferation,
5
essentially indefinitely without loosing their undifferentiated character.
This key characteristic significantly distinguishes stem cells from somatic
6
cells. Somatic cells undergo only a finite number of replications in
culture because of a sequential shortening of the chromosome ends
7
(telomeres) during each cell division. Stem cells, in contrast to human
somatic cells, express a protein (telomerase) that permits for the

2. Andrew Pollack, Agency Agrees to Review Human Stem Cell Patents, N.Y. TIMES,
Oct. 4, 2006, at C3.
3. See The National Institute of Health Resource for Stem Cell Research, Stem Cell
Basics (2006), available at http://stemcells.nih.gov/info/basics/defaultpage.asp.
4. Id.
5. Kevin A. D’Amour & Fred H Gage, Genetic and Functional Differences Between
Multipotent Neural and Pluripotent Embryonic Stem Cells, 100 PROC. NAT’L. ACAD. SCI. U.S.
11866 (2003).
6. Somatic cells are all body cells that are not stem cells or reproductive cells.
Wikipedia, Somatic Cell (May 28, 2007), http://en.wikipedia.org/wiki/Somatic_cells.
7. Richard J. Hodes, Telomere Length, Aging, and Somatic Cell Turnover, 190 J. EXP.
MED. 153, 153 (1999).
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maintenance of chromosome ends and thereby allows for indefinite
8
replication.
Embryonic stem cells (ES cells) retain the ability to form “all three
9
embryonic germ layers even after prolonged culture.” Adult stem cells,
those that are found in an individual’s tissues, are typically limited in
their ability to differentiate into only those cells inherent to the tissue in
10
which they reside. For example, adult stem cells in the brain (neural
stem cells) can differentiate into nerve cells, astrocytes, and
11
oligoddendrocytes, all of which reside in brain tissue. However, adult
stem cells that can differentiate into cells of tissues other than the one in
which they reside have been isolated and are currently under
12
investigation.
The great hope for ES cells rests in their use as replacements for
human tissues and organs that failed as a result of accidents, disease, or
13
age. For example, scientists speculate that ES cells could alleviate or
14
cure the insulin insufficiency in individuals suffering from diabetes. If
the ES cells could integrate into the pancreatic islets and become
insulin-producing cells, they would effectively ameliorate or even
15
completely cure the diseased phenotype. Similar hope exists in the
field of degenerative disorders, such as Alzheimer’s and Parkinson’s
16
diseases. In addition, stem cells are important study objects to discern
17
the human developmental process as well as biological processes.
8. James A. Thomson et al., Embryonic Stem Cell Lines Derived from Human
Blastocysts, 282 SCIENCE 1145, 1145 (1998).
9. Id. at 1146.
10. The National Institute of Health Resource for Stem Cell Research, What are Adult
Stem Cells? (2006), http://stemcells.nih.gov/info/basics/basics4.asp.
11. Id.
12. See, e.g., R. W. Mays et al., Development of Adult Pluripotent Stem Cell Therapies
for Ischemic Injury and Disease, EXPERT OPIN. BIOL. THER. 7(2):173 (2007). See also The
National Institute of Health Resource for Stem Cell Research, What are Adult Stem Cells?,
supra note 10. Yu et al., Induced PluripointStem Cell Lines Derived From Human Semantic
Cells, SCIENCE, November 20, 2007, http://www.sciencemag.org/cgi/content/abstract/1151526.
13. Junying Yu & James A Thomson, Chapter 1: Embryonic Stem Cells, in
REGENERATIVE MEDICINE, 4, (D.H.H. Sede), 2006, available at http://stem
cells.nih.gov/info/scireport/2006report.htm (Sept. 2, 2007) (follow “Chapter 1: Embryonic
Stem Cells” hyperlink).
14. Gretchen Vogel, Stem Cells: New Excitement, Persistent Questions, 290 SCIENCE
1672, 1673 (2000).
15. National Cancer Institute, What would you hope to achieve from human pluripotent
stem cell research? (2000), http://stemcells.nih.gov/news/newsArchives/achieve.asp.
16. Id.
17. See White House Press Release, Fact Sheet: Embryonic Stem Cell Research (Aug.
9, 2001), available at http://www.whitehouse.gov/news/releases/2001/08/20010809-1.html.
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However, it is important to note that this technology is still in its infancy
18
and its true value is unclear.
Currently, federal funds are available only for work with defined,
already-existing human embryonic stem cell lines, i.e. federal funding
may not be used to generate or work with new human embryonic stem
19
cell lines.
II. THE STEM CELL PATENTS
A patent grants the “right to exclude others from making, using,
20
offering for sale, or selling the invention.” The three stem cell patents
that are being reexamined are U.S. Patent numbers 5,843,780 (“Primate
21
embryonic stem cells,” “the ‘780 Patent”), 6,200,806 (“Primate
22
embryonic stem cells,” “the ‘806 Patent”), and 7,029,913 (“Primate
23
Embryonic Stem Cells,” “the ‘913 Patent”). The ‘780 Patent issued in
1998 and claims “purified preparation of primate embryonic stem
24
cells.” The ‘806 Patent issued in 2001 and claims “purified preparation
25
of pluripotent human embryonic stem cells.” The ‘913 Patent issued in
2006 and claims “methods of obtaining human hematopoietic cells from
human pluripotent embryonic stem cells using mammalian stromal
26
cells.” All three patents list Dr. James Thomson as the inventor, are

18. James A. Thomson, Embryonic Stem Cell Lines Derived from Human Blastocysts,
282 SCIENCE 1145, 1145-47 (1998).
19. Guidance for Investigators and Institutional Review Boards Regarding Research
Involving Human Embryonic Stem Cells, Germ Cells and Stem Cell-Derived Test Articles
(Mar. 19, 2002), [hereinafter Guidance]. See also, Diane T. Duffy, Background and Legal
Issues Related to Stem Cell Research, Congressional Research Service (2002); National
Institute of Health Resource for Stem Cell Research, What are Adult Stem Cells?, supra note
10. “Research on existing human embryonic stem cell lines may be conducted with Federal
support [only] if the cell lines meet the U.S. President’s criteria which he announced on
August 9, 2001.” OFFICE OF THE DIRECTOR, NIH, NOTICE OF CRITERIA FOR FEDERAL
FUNDING OF RESEARCH ON EXISTING HUMAN EMBRYONIC STEM CELLS AND
ESTABLISHMENT OF NIH HUMAN EMBRYONIC STEM CELL REGISTRY (2001),
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html
[hereinafter
NIH
NOTICE].
20. 35 U.S.C. § 154 (2006 & Supp. 2004).
21. Primate Embryonic Stem Cells, U.S. Patent No. 5,843,780 (filed Jan. 18, 1996)
(issued Dec. 1, 1998) [hereinafter “‘780 Patent”].
22. Primate Embryonic Stem Cells, U.S. Patent No. 6,200,806 (filed Jun. 26, 1998)
(issued Mar. 13, 2001) [hereinafter “‘806 Patent”].
23. Primate Embryonic Stem Cells, U.S. Patent No. 7,029,913 (filed Oct. 18, 2001)
(issued Apr. 18, 2006) [hereinafter “‘913 Patent”].
24. See ‘780 Patent, supra note 21.
25. See ‘806 Patent, supra note 22.
26. See ‘913 Patent, supra note 23.
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27

assigned to WARF, and are licensed to Geron Corporation.
This
California biotechnology company “has an exclusive license to the
28
Geron had
WARF patents for heart, pancreas and neural cells.”
29
provided significant financial support for Dr. Thomson’s research.
III. REEXAMINATION
30

“A patent shall be presumed valid.” To challenge the validity of a
31
patent, any person can apply for reexamination with the USPTO. The
grounds for which such reexamination may be requested are limited to
new questions of patentability raised by prior art, i.e. a printed
32
publication or patent. The requestor must make his request in writing
and explain the relevance of the cited prior art with regard to every
claim to be reexamined. For such a reexamination request to be
granted, the examiner has to find that the cited prior art raises “a
33
substantial new question of patentability.”
Prior art raises a
substantial new question of patentability if “there is a substantial
likelihood that a reasonable examiner would consider the prior art . . .
34
important in deciding whether or not the claim is patentable.”
While a patent owner could potentially lose his patent, a requestor
has nothing to lose because the USPTO refunds a large portion of the
reexamination application fee should the request for reexamination not
35
be granted. Requestors cannot appeal the USPTO’s decision not to
36
grant the request for reexamination.
The Public Patent Foundation, on behalf of the FTCR, filed a

27. ‘780 Patent, supra note 21; ‘806 Patent, supra note 22; ‘913 Patent, supra note 23.
28. Alex Lash, Government Nixes Stem-Cell Patents, THE FOUNDATION FOR
TAXPAYER AND CONSUMER RIGHTS (Apr. 4, 2007), available at http://www.con
sumerwatchdog.org/healthcare/nw/?postId=7671.
29. See id.
30. 35 U.S.C. § 282 (2000 & Supp. 2004).
31. 4 DONALD S. CHISUM, CHISUM ON PATENTS § 11.07 (2004).
32. U.S. PATENT & TRADEMARK OFFICE, U.S. DEP’T OF COMMERCE, MANUAL OF
PATENT EXAMINING PROCEDURE § 2216 (8th ed. 2006) [hereinafter MPEP]. Under 35
U.S.C. 304, the Office must determine whether “a substantial new question of patentability”
affecting any claim of the patent has been raised. 37 C.F.R. 1.510(b)(1) requires that a
request for ex parte reexamination include “a statement pointing out each substantial new
question of patentability based on prior patents and printed publications.” Id.
33. 35 U.S.C. § 303(a) (2006).
34. MPEP § 2242 (2006).
35. Id. at § 1.26(c) (2006).
36. 35 U.S.C. § 303(c) (2006 & Supp. 2004).
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request for reexamination of the three stem cell patents in July, 2006.
The FTCR cited five sources, only four of which were deemed by the
38
USPTO to raise “a substantial new question of patentability.” The
fact that the FTCR’s request for reexamination was granted is not
unusual. The USPTO grants between 90% (ex parte) and 98% (inter
39
partes) of reexamination requests. The claims at issue were changed in
some way in nearly two-thirds of the ex parte proceedings, but all claims
40
were cancelled in only 10% of the proceedings. The challenged claims
remained unaltered in more than one-fourth of the proceedings. Since
90% of all reexamination proceedings resulted in either modified or
unaltered claims and only 10% in cancellation, the USPTO history
makes it unlikely that the FCTR will prevail in its desired cancellation
of the ‘780 Patent and the ‘806 Patent. In contrast, for the ‘913 Patent,
an inter partes proceeding was granted. In inter partes proceedings, less
than one-third of the claims remained unaltered or were modified, while
41
over 70% were cancelled.
On April 3, 2007, the USPTO issued a preliminary rejection of the
42
stem cell patents due to obviousness. This is not unusual, however,
43
and signifies only the first of many steps. In its response filed on May
44
31, 2007, WARF refutes the USPTO’s preliminary rejection. Further
proceedings are likely to take months, if not years.

37. WARF Stem Cell Patents, Public Patent Foundation (2007), http://www.pub
pat.org/warfstemcell.htm.
38. 35 U.S.C. § 303(a) (2006).
39. Joseph D. Cohen, What’s Really Happening in Inter Partes Reexamination, 87 J.
PAT. & TRADEMARK OFF. SOC’Y 207, available at http://www.stoel.com/Files/InterPartes.pdf
(last visited Sept. 20, 2007). An ex parte reexamination “allows a challenger to initiate a
review by producing prior art . . . but . . . excludes the challenger from further participation in
the examination process.” BLACK’S LAW DICTIONARY 1306 (8th ed. 2004). An inter partes
reexamination “allows a challenger to initiate a review by producing prior art, to respond to a
patentee's statements regarding the new prior art, to address the patentee's responses to any
office actions, and to request a hearing.” Id.
40. See id.
41. See id.
42. Andrew Pollack, 3 Patents on Stem Cells are Revoked in Initial Review, N.Y. TIMES,
Apr. 3, 2007, at C2.
43. See 37 C.F.R. §§ 1.510-1.570 (2006); MPEP § 2201 (8th ed. 2006) (displaying
flowcharts on reexamination).
44. WARF, Wisconsin Alumni Research Foundation Defends Patents in Response to
Initial U.S. Patent and Trademark Office Action, (May 31, 2007), http://www.warf.org/
news/news.jisp?news_id=212. The response is available at http://www.warf.org/uploads/
media/WARF_Response_to_PTO_Action_without_exhibits.pdf.
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IV. SHOULD THE PATENTS REMAIN VALID?
The WARF patents should remain valid because the prior art cited
by the requestors does not render the inventions obvious. Also, the
patents should remain valid because they do not stifle but rather
promote the progress of science by allowing access to those who want it
for a reasonable fee (or no fee at all). Finally, the patents should remain
valid to foster investors’ confidence in investing in embryonic stem cell
research so that such research can continue despite current restrictions
on available federal funding.
A. Obviousness
45

To be patentable, an invention must be novel and useful as well as
46
nonobvious. “Nonobviousness . . . means that an invention must not
have been obvious to one with ordinary skill in the art to which the
subject matter of the invention pertains at the time of the invention and
47
in the light of . . . the prior art.” In contrast to novelty, an invention
can be obvious even in the absence of a single prior reference as long as
all components are described in prior references and “some motivation
or suggestion to combine the references is provided by the prior art
48
taken as a whole.” It should be noted that this general standard of
49
nonobviousness was recently rejected by the Supreme Court. It is not
entirely clear yet how this decision will impact biotechnological
inventions. However, it is speculated that “the impact of the Supreme
50
Court’s ruling may not be as profound on life-science patents.” This
notion is supported by the fact that “[w]ith life science inventions, ‘we
can extrapolate and guess, but until we conduct an experiment, we don’t
51
know if it’s going to work.’”
When dealing with biotechnological inventions, the standard for
obviousness has been more difficult to define. In 1995, Congress
amended 35 U.S.C. § 103 with subsection (b) to include a provision
52
specific to biotechnology. This subsection “has been interpreted as
45.
46.
47.
48.
49.
50.

35 U.S.C. §§ 101 and 102 (2006 & Supp. 2004).
Id. § at 103(a).
2 DONALD S. CHISUM, CHISUM ON PATENTS § 5.01 (2004).
Id. at § 5.04[1][e][ii] (citing In re Beattie, 974 F.2d 1309, 1312 (Fed. Cir. 1992)).
KSR Int’l Co. v. Teleflex, Inc., 127 S. Ct. 1727 (2007).
Joe Vanden Plas, Supreme Court Ruling Seen as Blow to WARF Stem Cell Patents,
WISCONSIN TECHNOLOGY NETWORK (May 2, 2007), http://wistechnology.com/article.
php?id=3889.
51. Id.
52. 35 U.S.C. § 103(b) (2006 & Supp. 2004).
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requiring that the prior art lead to the production of the invention and
that there be a reasonable expectation that the invention can be carried
53
out successfully for the invention to fail the non-obvious requirement.”
54
55
56
Robertson, Piedrahita, and Robertson, three of the cited prior
art references in the application for reexamination, exclusively use and
57
discuss animal models, mostly murine. There is no doubt that murine
(1) Notwithstanding subsection (a), and upon timely election by the applicant for
patent to proceed under this subsection, a biotechnological process using or
resulting in a composition of matter that is novel under section 102 and nonobvious
under subsection (a) of this section shall be considered nonobvious if-(A) claims to the process and the composition of matter are contained in
either the same application for patent or in separate applications having the
same effective filing date; and
(B) the composition of matter, and the process at the time it was invented,
were owned by the same person or subject to an obligation of assignment to the
same person.
(2) A patent issued on a process under paragraph (1)-(A) shall also contain the claims to the composition of matter used in or
made by that process, or
(B) shall, if such composition of matter is claimed in another patent, be set
to expire on the same date as such other patent, notwithstanding section 154.
(3) For purposes of paragraph (1), the term "biotechnological process" means-(A) a process of genetically altering or otherwise inducing a single- or
multi-celled organism to-(i) express an exogenous nucleotide sequence,
(ii) inhibit, eliminate, augment, or alter expression of an endogenous
nucleotide sequence, or
(iii) express a specific physiological characteristic not naturally
associated with said organism;
(B) cell fusion procedures yielding a cell line that expresses a specific
protein, such as a monoclonal antibody; and
(C) a method of using a product produced by a process defined by
subparagraph (A) or (B), or a combination of subparagraphs (A) and (B).
Id.
53. Damon J. Whitaker, The Patentability of Embryonic Stem Cell Research Results, 13
U. FLA. J.L. & PUB. POL’Y 361, 370 (2002).
54. ELIZABETH J. ROBERTSON, Isolation, Properties, and Karyotype Analysis of
Pluripotential (EK) Cell Lines from Normal and Parthenogenetic Embryos, in
TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, 71-112
(Elizabeth J. Robertson ed., IRL Press, Oxford 1987).
55. J.A. Piedrahita et al., On the Isolation of embryonic Stem Cells: Comparative
Behavior of Murine, Porcine and Ovine Embryos, 34 THERIOGENOLOGY 879 (1990).
56. ELIZABETH J. ROBERTSON, Embryo-derived stem cell lines, in TERATO
CARCINOMAS AND EMBRYONIC STEM CELLS; A PRACTICAL APPROACH, 71-112 (Elizabeth
J. Robertson ed., IRL Press, Oxford 1987).
57. The term “murine” is used by scientists to refer to a mouse, but includes all things
“of or relating to a murid genus (Mus) or its subfamily (Murinae) which includes the common
household rats and mice.” MERRIAM-WEBSTER ONLINE DICTIONARY, http://www.m-
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embryonic stem cells have been isolated and cultured, at least to a
certain extent, prior to the successful culture of human embryonic stem
cells. However, these previous experiments do not render the patented
technology obvious.
First, the vast majority of technologies designed for human
58
applications have some form of animal test precursor. It is neither
practical nor economical, let alone ethical, to conduct initial
59
experimentations on humans. Therefore, virtually every experiment,
trial, or treatment with human tissue had to begin with animal
experimentation. It would defeat the purpose of the patent system to
allow for individuals that conduct the preliminary animal experiments to
claim exclusive rights to any possible human applications without having
had successfully translated the technology at issue to human tissue.
Patents grant the right to exclude others from making and using an
60
invention.
Researchers should not be allowed to “call dibs” on a
technology that was never successfully reduced to practice in humans
merely because successful animal experimentation has been conducted.
Neither should such animal experimentation render the human
application obvious so as to make it unpatentable for any researcher
who adapts the technology for human application. This would
discourage researchers from communicating possible alternative species
applications of the technology to others. Rather, it would encourage
researchers to keep their animal data under a veil of secrecy to preclude
the possibility of barring themselves from possible application to other
species. Secrecy is the very thing the patent system intends to
61
discourage.
Second, an obviousness rejection requires that the “prior art
suggests to a person of ordinary skill in the art to make the claimed
62
63
invention.” In other words, the prior art made it “obvious to try.”
w.com/dictionary/murine (last visited Sept. 30, 2007).
58. See, e.g., 45 C.F.R. § 46 (2006).
59. See, e.g., David J. Rothman, Ethics and Human Experimentation: Henry Beecher
Revisited, 317 NEW ENG. J. MED. 1195 (1987); Joseph V. Brady & Albert R. Jonsen, The
Evolution of Regulatory Influences on Research with Human Subjects, in HUMAN SUBJECTS
RESEARCH – A HANDBOOK FOR INSTITUTIONAL REVIEW BOARDS (Robert A. Greenwald
et al. eds., Plenum Press 1982).
60. See 35 U.S.C. § 154(a)(1) (2006 & Supp. 2004); 35 U.S.C. § 271 (2006 & Supp.
2004).
61. See Gideon Parchomovsky, Publish or Perish, 98 MICH. L. REV. 926 (2000).
62. DONALD S. CHISUM ET AL., PRINCIPLES OF PATENT LAW 617 (Foundation Press
3rd ed. 2004).
63. In re O’Farrell, 853 F.2d 894, 902 (Fed. Cir. 1988).
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However, an invention that is obvious to try is not necessarily obvious
64
under Section 103. A second requirement for an obviousness rejection
under Section 103 is that there must be a “reasonable expectation of
65
success.”
This second requirement is important because otherwise
everything that is obvious to try would be unpatentable. In other words,
while people may have thought of trying to make a given invention,
nobody has the incentive to invest in actually going forward with the
research because their investment cannot be returned in the absence of
patent protection. Such a view would clearly defeat the purpose of the
patent system.
Even if the FTCR could establish that there was a suggestion in the
prior art to establish human stem cells, it lacks the second required
showing, the expectation of success. In fact, as discussed in the next
paragraph, the prior art, if anything, teaches away from establishing
human stem cells.
Third, several promising technologies have not yet been tried on
human subjects because the interspecies differences make initial success
66
unlikely.
This is especially true for experiments that have been
conducted with the experimental animal most scientists work with, the
mouse. In the case of stem cells, “[h]uman and murine ESCs differ from
67
These differences affect
each other in a wide spectrum of genes.”
68
Most
growth rates, culture requirements, and marker expression.
importantly, these differences affect pathways required to maintain the
69
stem cell phenotype. Although the details and underlying mechanisms
of those differences are only recently being elucidated, the fact that
human cells are not identical to murine cells is evident because it took
scientists almost a decade to replicate the murine experiments in human
70
cells. The “derivation and manipulation of murine stem cells was an
71
elite skill.” “[T]he manipulation of [human embryonic stem cells is] an
even more highly skilled art and one that few scientists have yet
64. See id. at 902-04.
65. Id. at 904.
66. See Gretchen Vogel, Four Genes Confer Embryonic Potential, 313 SCIENCE 27
(2006).
67. Chia Lin Wei et al., Transcriptome Profiling of Human and Murine ESCs Identifies
Divergent Paths Required to Maintain the Stem Cell State, 23 STEM CELLS 166, 173 (2005).
68. Id. at 167.
69. Id.
70. See, e.g., Wikipedia, Key E Stem Cell Research Events (Aug. 31, 2007),
http://en.wikipedia.org/wiki/Stem_cell.
71. Melissa Little, Wayne Hall, & Amy Orlandi, Delivering on the Promise of Human
Stem-Cell Research, 7 EMBO REPORTS 1188, 1191 (2006).
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72

mastered.”
It is important to remember that this is not an area of science that
was inactive and has only now become popular. Quite the opposite is
true; stem cell research is one of the “hottest” areas of scientific
research because of its enormous potential to revolutionize the way
73
medicine is practiced. In fact, scientists have desired success in this
area so much that it has led some to falsify research results and pretend
74
to have been successful.
Even if a prima facie case of obviousness can be established, it can
75
be rebutted by secondary considerations. In Graham v. John Deere
Co., the Supreme Court enumerated such secondary considerations that
can rebut a prima facie case of obviousness, which are (1) commercial
76
success; (2) long-felt but unsolved need; and (3) failure of others.
With regard to the WARF patent, all three considerations clearly
weigh against obviousness. The patented technology is commercially
successful because the patents have resulted in a large number of
77
licensing agreements as well as the formation of start-up companies.
There was a long-felt but unsolved need in the scientific arena to
establish human embryonic stem (“hES”) cell cultures. As mentioned
above, even after successfully practiced with murine cells, it took several
78
more years before human embryonic cell lines were established.
Finally, it is difficult to estimate how many other scientists have tried
but failed to grow stable hES cells in vitro. However, given the

72. Id.
73. The National Institute of Health Resource for Stem Cell Research, Frequently
Asked Questions, http://stemcells.nih.gov/info/faqs.asp (last visited Sept. 2, 2007); Fiona M.
Watt & Kevin Eggan, Molecular Mechanisms of Stem-Cell Identity and Fate, NATURE
REVIEWS, available at http://www.nature.com/nrc/posters/stemcell/index.html (last visited
Sept. 30, 2007).
74. S Korea Scientist on Fraud Charge, BBC NEWS (May 12, 2006),
http://news.bbc.co.uk/2/hi/asia-pacific/4763973.stm; Nathan Seppa, Stem Cell Controversy:
Scientist is Retracting Landmark Finding, SCIENCE NEWS ONLINE (Dec. 24, 2005),
http://www.sciencenews.org/articles/20051224/fob7.asp.
75. Graham v. John Deere Co., 383 U.S. 1, 18-19 (1966).
76. Id. at 17.
77. “WiCell has distributed cells to more than 360 research groups in 40 states and 24
countries. . . . [O]f all of the academic papers published in scientific journals between 2002
and 2004, a full 67 percent used [the WARF] cells. . . . Over the past year, the number of
WARF commercial licenses has doubled, reflecting an increase in industry-supported
research and development.” Wisconsin Alumni Research Foundation Changes Stem Cell
Policies to Encourage Greater Academic, Industry Collaboration, WARF NEWS, Jan. 23, 2007,
http://www.warf.org/news/news.jsp?news_id=209.
78. Wei et al., supra note 67, at 167.
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enormous excitement and anticipation for hES cell research in the
academic as well as industry settings, it can be presumed that numerous
other scientific groups have unsuccessfully tried to achieve this goal.
For example, Time Magazine described Dr. Thomson as “one of the
people ‘who are changing the world’ and . . . Science . . . called his
invention ‘one of the most significant milestones in the history of
79
science.’” Further, Dr. Thomson has obtained countless awards and
80
recognitions for his achievements in stem cell research. This portrayal
of Dr. Thomson’s work by lay as well as scientific journals and
institutions demonstrates that “‘at the time of the discoveries, leading
scientist and scholars from around the world saw Thomson as the first
81
scientist to isolate and proliferate human embryonic stem cells.’”
Therefore, even if a prima facie case of obviousness could be
established, it could easily be rebutted with these secondary
82
considerations.
B. The Validity of the Stem Cell Patents Is Consistent with the Purpose
of Patent Law
The constitutional objective of patents is to “promote the Progress
83
of Science.”
In other words, the purpose of the patent system is to provide
84
incentives for invention and creation. However, science for science’s
sake is rare these days. Although most scientists do not conduct their
research with a patent in mind, the organization for which the scientists

79. Joe Vanden Plas, WARF Questions Relevancy of Documents Used to Uphold Patent
Challenge, WISCONSIN TECHNOLOGY NETWORK (May 31, 2007), http://wisconsintech
nology.com/printarticle.php?id=3965.
80. See, e.g., University of Wisconsin-Madison Endocrinology-Reproductive
Physiology Program Faculty Webpage for Dr. James Thomson, http://www.erp.wisc.edu/
faculty/thomson.html (last visited Sept. 9, 2007) (listing such awards as: American Academy
of Achievement Golden Plate Award (1999); World Technology Award Finalist, Health and
Medicine, The Economist-London (1999); Man of the Year, Madison Magazine (2001); Hall
of Fame Award for Scientific Achievement, 15th Annual Conference of Biotechnology CEOs
(2001); Featured as "One of the most intriguing people of 2001," People Magazine (2001);
Featured as one of eighteen scientists representing "America’s Best in Science and
Medicine,” Time magazine (2001); Wilson S. Stone Memorial Award for Biomedical
Research (2001); Lois Pope Award Annual LIFE International Research Award (2002)).
81. Vanden Plas, supra note 79 (quoting WARF managing director).
82. MPEP § 1504.03(III) (8th ed. 2006).
83. U.S. CONST. art. I, § 8, cl. 8.
84. See, e.g., Sinclair & Carroll Co., Inc. v. Interchemical Corp., 325 U.S. 327, 330-31
(1945).
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85

work probably does. Both universities and private companies have a
86
vested interest in developing and protecting intellectual property;
many funding sources look to the patent portfolio, or patenting
potential, of such organizations before even considering making an
investment. Thus, from the organization’s point of view, the objective is
not only for the scientist to conduct his or her research, but is also for
investors to fund such research. “Investors in any new technology are
87
Without the possibility of
concerned to protect their investment.”
patent protection of a research product, investors would be far less
likely to invest because the opportunities for financial return would be
minimal. In other words, the investors would carry the risk and would
have marginal expectations of return.
88
This is especially true for stem cell research. “Investors have . . .
been reluctant to make . . . investments into [related research] for a
89
number of good reasons.”
Among those reasons is the concern
whether future intellectual property protection is possible should useful
90
results be obtained. “[R]isk aversion among potential investors is a
91
real barrier to . . . this research.”
Thus, solid patent protection of
current and future technology is critical to the progress of science
because it vitally depends on private investments, especially in the
absence of federal funding.
Society is gaining many things from the patent protection of an
invention. One of the most important is disclosure. The tradeoff for
obtaining this temporary monopoly is that the patent holder has to
disclose the invention and enable someone with ordinary skill in that art
92
to reproduce or use the invention.
It is true that “unwarranted monopoly power must be vigilantly
93
guarded against.”
85. See, e.g., Stacey Higginbotham, How Open? That's the Big Patent Question, CNET
News.com, Sept. 25, 2005, http://news.com.com/How+open+Thats+the+big+patent+question
/2100-1014_3-5877028.html.
86. See, e.g., Nathaniel Lipkus, How to Understand Product Development: PublicPrivate Partnerships as Vehicles for Innovation in Combating Neglected Disease, 10 MICH. ST.
J. MED. & LAW 385 (2006).
87. Gareth Williams, Patenting of Stem Cells, 1 REGEN MED. 697 (2006).
88. See Little, supra note 71, at 1191.
89. Id. at 1190.
90. Id. at 1191.
91. Id.
92. 35 U.S.C. § 112 (2006).
93. Christopher D. Hazuka, Supporting the Work of Lesser Geniuses: An Argument for
Removing Obstructions to Human Embryonic Stem Cell Research, 57 U. MIAMI L. REV. 157,
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However, WARF is not in possession of such an unwarranted
monopoly. WARF permits scientists to use the invention during the
patent’s lifetime with only a few restrictions.
One can hardly
characterize WARF’s use of its patent as rendering the monopoly
“unwarranted.” It merely protects the investors’ capital that enabled
the research culminating in these stem cells.
Investment enables research. This is especially true since no federal
94
funding is currently available for the generation of new hES cell lines.
Any research in this area has to be funded through private investments.
Private investment was what made Thomson’s research possible as well.
The stem cell project would never have been able to go forward without
Geron’s funding for the University of Wisconsin. Geron would not have
funded research that is purely academic with no prospect of financial
return for the company. In fact, such a decision would have been
95
against the business purpose to maximize shareholder wealth.
Financial return can be secured only through the protection of a patent.
It can hardly be true that the WARF patents stifle research. Quite
the opposite is true.
Scientific progress is accelerated because
researchers can use the WARF ES cells, rather than having to establish
their own ES cell lines. Furthermore, the patents act as incentives for
scientists to explore other avenues to design around the patents. It is
important to remember that WARF “did not contract for limitations on
96
[California’s] ability to compete.” WARF “may compel rivals . . . to
do more work to develop [alternatives] independently, but this
97
promotes rather than restricts competition.” For example, promising
research has come from the generation of pluri-potent cells from
98
somatic (adult body) cells.
In addition, StemCells, Inc. obtained a
patent on generating human neural stem cell cultures from “embryonic .

172 (2002).
94. “Research on existing human embryonic stem cell lines may be conducted with
Federal support [only] if the cell lines meet the U.S. President’s criteria which he announced
on August 9, 2001.” NIH NOTICE, supra note 19. See also Duffy, supra note 19.
95. Dodge v. Ford Motor Co., 170 N.W. 668, (684 Mich. 1919) (“A business
corporation is organized and carried on primarily for the profit of the stockholder.”).
96. Idx Sys. Corp. v. Epic Sys. Corp., 285 F.3d 581, 585 (7th Cir. 2002) (stating that
non-disclosure agreements are not subject to the same restrictions as non-compete
agreements).
97. Id.
98. Gretchen Vogel, Researchers Turn Skin Cells into Stem Cells, SCIENCENOW
DAILYNEWS, November 20, 2007, http://sciencenow.sciencemag.org/cgi/content/full/2007/112
0/1.
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99

. . fetal, neonatal, and adult tissue.”
Other human embryonic stem cell lines might be created via a
different, perhaps better, method in the future. Without the patent,
there would be no need to invest research dollars into designing such
new techniques. Therefore, the patent acts as an incentive for future
scientific research in the field of stem cell research. “No one doubts this
with physical property: General Motors is entitled to control 100% of
its own output of mufflers, without handing any of them over to Ford or
100
Toyota or Volkswagen.”
C. Disclosure
One of the goals of the patent system is “to motivate disclosure of
inventions and reduce the use of trade secrets as a method of protecting
101
intellectual property.”
This is especially important for the biological
sciences. First, due to the high cost of conducting biomedical research,
it is important not to use tax dollars to fund research that merely
duplicates scientific research already conducted. Only when findings
are disclosed, not concealed, can such duplicative research be avoided.
Second, the ability to disclose scientific findings is the life-blood of
scientists. Publications in peer-reviewed journals and presentations at
national or international meetings allow the scientist to share his or her
result with the scientific community. Thereby, the scientist does not
only disseminate his knowledge to others but may get valuable feedback
from other scientists, establish collaboration among institutions, and
gain valuable recognition in his field of study. Without publishing the
results of his or her research, the scientist cannot establish a track
record in the scientific community. Without a track record, it will be
challenging for the scientist to obtain funding for future research
undertakings.
Thus, disclosing his research results serves many
important functions that propel scientific research at large. However,
scientists that make disclosures without the protection of a patent may
find themselves barred from continuing with their research because
102
someone else “scooped” them. Publications are typically reviewed for
99. Posting of Douglas Sorocco to Phosita | An Intellectual Property Law Blog!, US
Stem Cell Patent Issued, http://www.okpatents.com/phosita/archives/2004/08/us_stem_cell_pa
.html (Aug. 23, 2004, 12:44 CST).
100. Idx Sys. Corp., 285 F.3d at 585.
101. David J. Weitz, The Biological Deposit Requirement: A Means of Assuring
Adequate Disclosure, 8 HIGH TECH L.J. 275, 298 (1993).
102. A patent provides the “right to exclude others from making, using, offering for
sale, or selling the invention.” 35 U.S.C. § 154(a)(1) (2006). Should an inventor disclose his
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novelty. Thus, if someone else has published the same results
elsewhere, the editors of another journal are unlikely to accept an
article with the same results.
Grants of patents are useful not only to the owner but also to the
public, especially with regard to break-through scientific findings in the
biosciences. This is due to the fact that, in the special case of biological
103
material, a patentee may be required to make a deposit with the PTO.
104
Because it is often
Such a deposit is available for public inspection.
impossible for other researchers to reproduce a biotechnological
invention, the interest of the pertinent scientific community is
105
The patentee “has a
safeguarded through a patent on the invention.
strong economic incentive” to keep his biological material inaccessible
106
to the public.
A patent, however, allows for the researcher to share
his findings safely with the public.
D. Not Research but Profit-Making Is Limited by the Patents
The Patents, especially ‘806, are quite broad and may therefore be
vulnerable. Nevertheless, the USPTO should not invalidate the patents.
It is clear what the patents would not cover, i.e., the generation of stem
cells from somatic tissue or by nuclear transfer.
Experiments
107
attempting this task are currently underway.
The patents do not
describe the one and only method to generate stem cells and maintain
the desired embryonic phenotype and genotype in vitro.
Experimentation for new methodology is currently only possible
through private funding frustrating academic scientists. However,
academic scientists do not need to generate other cell lines because they
108
It should be noted
can use the patented cell lines for a minimal fee.
that “WARF imposes no restrictions on patenting or publishing the
109
results of basic academic research.” Research itself is thus not stifled.
invention without this protection, other companies or individuals are free to duplicate and
practice the invention.
103. See 37 C.F.R. §§ 1.801-1.809 (2006); 37 C.F.R. § 1.93 (2006); MPEP Appendix R,
Patent Rules § 1.93 (8th ed. 2006).
104. 37 C.F.R. § 1.808(c) (2006).
105. See Weitz, supra note 101.
106. Id. at 299-300.
107. See, e.g., Jeffrey M. Perkel, Life Science Technologies Stem Cells: Beyond Somatic
Cell Nuclear Transfer, SCI. MAG., Apr. 4, 2007, available at http://www.sciencemag.org/prod
ucts/lst_20070420.dtl.
108. See infra Part V.G.
109. Posting of Kevin E. Noonan to Patent Docs, It’s Time to Stop the Hypocrisy over
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Rather, the licensing conditions limit the amount of commercial profit
companies can make using the patented invention. Limits imposed onto
the ability of individuals or companies to profit from an invention that
was patented by another can hardly be a reason for finding a patent
invalid.
E. The Upstream Technology Argument
Opponents of the WARF patents argue that the patents cover
110
In other words, stem cells can be useful for
“upstream” technology.
making future biotechnological discoveries and inventions. However,
an “upstream-downstream” distinction can hardly be made in
biotechnology because there is no workable line-drawing mechanism.
Even if there was a method to distinguish what is and what is not
upstream technology, it would hardly be reasonable to propose that
upstream technology is generally unpatentable. Upstream technology
111
should especially be patentable because it includes all pioneer work.
For most inventions, especially in biological sciences, the true
significance is rarely clear. For example, in the 1940s, two scientists
112
studied a virus that infects bacteria.
Perhaps some were wondering
why it would be of any significance to study these bacteriophages. Most
certainly, the discovered methods and observations would not have
been characterized as upstream technology. Later, it became clear that
the two scientists, Max Delbrück and Salvador Luria, had developed a
simple model system for DNA transfer, the first cloning of genetic
113
information. This simple example illustrates that characterizations of
technological advancements as “upstream” or “not upstream” are
hardly possible. The potential for future scientific use rests in every
scientific discovery. Thus, essentially all technologies are “upstream” in
some way. One cannot punish an inventor by making his discovery
unpatentable simply because his or her invention is highly useful.
Stem Cell Patent – Part II, available at http://patentdocs.typepad.com/patent_docs/2007/04/its_
time_to_sto_1.html (Apr. 26, 2007).
110. See, e.g., Amy Rachel Davis, Patented Embryonic Stem Cells: The Quintessential
"Essential Facility"?, 94 GEO. L. J. 205 (2005).
111. A pioneer work or invention refers to something entirely new rather than an
improvement within an existing branch of science. See James E. Rogan, Prepared Remarks
at the Hearings on Competition and Intellectual Property Law and Policy in the KnowledgeBased Economy (Feb. 6, 2002), available at http://www.uspto.gov/web/offices/com/comm
06feb2002.html.
112. S. E. Luria & M. Delbrück, Mutations of Bacteria from Virus Sensitivity to Virus
Resistance, 28 GENETICS 491 (1943).
113. Id.
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Formerly, the government provided funding for “premarket or
‘upstream’ research and encouraged broad dissemination of results in
114
the public domain.”
However, because the technology was freely
available, commercial development was unattractive to investors. To
remedy this situation, Congress encouraged patenting of federally
115
Patent protection provided the needed
funded research results.
economic incentive to encourage investors to support research as well as
116
commercial development.
Critics argue, however, that “[a]
proliferation of intellectual property rights upstream may be stifling lifesaving innovations further downstream in the course of research and
117
product development.” The obvious counterargument to this criticism
is that upstream innovations would never be made without the
expectation of financial returns. “Scientific research is an expensive
118
Funding for such research would be unavailable and
endeavor.”
“[c]ommercialization would be impossible if not for the temporary
119
monopoly rights.”
F. WARF Is Not “Keeping It All to Itself”
The FTCR argues that the patents should be invalid because of the
danger that WARF will keep stem cell research to itself and thereby
120
stifle the scientific progress. Nothing could be further from the truth.
Science is rarely conducted in a vacuum. In fact, the scientific
community operates to support and inspire its constituents. Therefore,
it is not in WARF’s interest to keep the benefits of embryonic research
to itself.
WARF has not only shared the patent with over 400 scientists
121
worldwide, but has also included training for a reasonable royalty or
122
Further, scientists at the NIH and FDA, as well as
free of charge.
114. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anitcommons in Biomedical Research, 280 SCIENCE 698, 698 (1998).
115. See id.
116. See id.
117. Id.
118. Diana A. Villamil, Redefining Utility in Determining the Patentability of DNA
Sequences, 5 J. MARSHALL REV. INTELL. PROP. L. 238, 252 (2006).
119. Id.
120. John M. Simpson, Wisconsin Group Eases Stem Cell Patent Restrictions After
FTCR – PubPat Challenge, January 23, 2007, http://www.pubpat.org/warfstemcelleased.htm.
121. Elizabeth L.R. Donley, How Wisconsin Moved to the Front Line of Stem Cell
Research, MILWAUKEE J. SENTINEL, Sept. 2, 2006, available at http://www.jsonline.com/
story/index.aspx?id=489946.
122. See WiCell Research Institute – Technical Classes,
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scientists within the State of Wisconsin, are free to use the technology
123
without paying any royalty. There are not many examples where the
owner of a patent shares its protected invention as extensively as
WARF does right now.
It is also worth noting that the patented technology is not simply
blocking others from practicing the technique. Scientists at the
124
University of Madison and at the WiCell Research Institute have been
enormously prolific.
This productivity is reflected in successful
competition for research grants, thirty-eight peer-reviewed publications,
125
Using the patented stem cells,
and over thirty patent applications.
scientists have produced blood and plasma supplies, generated “insulinproducing cells to develop new treatments for diabetes,” and were
successful in restoring motor movement in several animal models by
126
regenerating spinal cord tissue.
Finally, WiCell is giving back to the public, which initially funded
some of the research that resulted in the patented invention. It is doing
so not only through the furthering of research, as discussed above, but
also through raising public awareness of stem cell technology.
Specifically, “the institute already offers one- and three-day courses for
127
journalists and teachers.”
In a few months, WiCell will launch a
“major public education initiative” to educate anyone interested in this
important technology and its potential in improving the way medicine is
128
Thus, the WARF patents are most certainly not
practiced today.
129
“stopping . . . domestic human ES cell research at its infancy.”

http://www.wicell.org/index.php?option=com_content&task=blogsection&id=16&Itemid=149
(last visited Jan. 11, 2008).
123. The NIH signed a memorandum of understanding with WARF and its subsidiary
WiCell. See Press Release, National Institute of Health, National Institutes of Health and
WiCell Research Institute, Inc., Sign Stem Cell Research Agreement (Sept. 5, 2001), available
at http://www.nih.gov/news/pr/sep2001/od-05.htm.
124. WiCell is a non-profit supporting organization of the University of Madison to
advance the science of stem cells. See WiCell and The National Stem Cell Bank Home Page,
http://www.wicell.org (last visited Sept. 2, 2007).
125. Carl Gulbrandsen, Stem-Cell Patent Holder’s View of the California Challenge,
WIS. TECH. NETWORK (Nov. 16, 2004), http://wistechnology.com/printarticle.php?id=1352.
126. Donley, supra note 121.
127. Id.
128. Id.
129. See Letter from Foundation for Taxpayer and Consumer Rights to USPTO (Mar.
13, 2001), available at http://www.pubpat.org/assets/files/warfstemcell/806Request.pdf (Sept.
21, 2006) (requesting reexamination of U.S. Patent No. 6,200,806).
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G. The Cost Is More Than Reasonable
The embryonic stem cells are available for a reasonable fee.
Scientists at academic institutions can obtain free licenses and a vial of
130
embryonic stem cells for $500. This fee includes scientific training to
131
enable interested researchers to work with the cells effectively.
This
fee is not only reasonable but in fact quite affordable. For example, a
single vial of murine embryonic stem cells costs $250 at the American
132
This ATCC fee does not include
Type Culture Collection (ATCC).
133
Also, the same hES cells cost $6,000 when provided by
any training.
134
ES Cell International, a company located in Singapore.
Importantly, the fee is reasonable when considering that it would
take tens of thousands of dollars to create an equivalent cell line
independently. The cost of salaries, tissue culture media, sterile culture
dishes, disposable pipette tips, etc., would exceed $500 in just a day.
Generating a comparable cell line could take years. Thus, the cost for
the cell line is reasonable and affordable for any academic scientists that
desire to work with these cells. Licensing costs for commercial entities
135
But these fees are not burdensome to
are considerably higher.
companies, and “it would be unrealistic (and inequitable) for a company
136
to obtain the cells for a simple licensing fee.” However, the fact that
commercial entities have to invest several thousand dollars before they
can utilize the patented technology should not render the patent invalid.
H. California v. Wisconsin?
California proclaims that “[b]y nearly any measure, California is the
137
national leader in innovation.” Further, “California is responsible for
one in four patents, attracts half of all venture capital and provides 20
percent of [all] technology jobs in the United States. From [its] world-

130. Pollack, supra note 42, at C2.
131 See WiCell Research Institute – Unlocking the Potential of Human Embryonic
Stem Cells, http://www.wicell.org/index.php?option=com_frontpage&Itemid=102 (last visited
Jan. 11, 2008).
132. ATCC: Cell Biology Collection, http://www.atcc.org/common/catalog/numSearch/
numResults.cfm?atccNum=SCRC-1029 (last visited Aug. 31, 2007).
133. See Pollack, supra note 42.
134. ESI – Stem Cell Products – Order hES, http://www.escellinternational.com/stem
cellprod/ordercells.htm (last visited Aug. 31, 2007).
135. $75,000 to $400,000. Pollack, supra note 38.
136. Noonan, supra note 109.
137. Governor Arnold Schwarzenegger, State of the State Address (Jan. 9, 2007),
available at http://gov.ca.gov/sots/research_innovation.html (last visited Jan. 9, 2007).
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leading stem cell research initiative to renewable energy and alternative
138
It has “the world’s
fuels, California is the birthplace of innovation.”
largest concentration of biotechnology companies” and because of its
commitment to stem cell research, it “has other countries treating the
139
state like it is its own nation.”
There can be no doubt that the numerous outstanding scientists at
California’s universities as well as in industry form a highly productive
network. To support research development and maintain California’s
“world-leading” position in the scientific arena, California voters
140
approved a funding initiative for stem cell research.
The state is
proposing a budget of $300 million per year over the next ten years in
California, which exceeds the NIH’s annual spending for the entire
141
nation tenfold.
The geographical location of the adverse institutions may not be
coincidental to the pending reexamination. It has been speculated that
142
the challenge is “politically and financially motivated” and would not
have been brought forward had the patent been owned by a California
institution. It is conceivable that, had a California institution owned the
stem cell patents, the validity of the patents would not have been
questioned.
In 2004, after the Bush administration had announced its restrictions
143
on stem cell research, California amended its constitution with the
144
California Stem Cell Research and Cures Initiative. This amendment
renders stem cell research a constitutional right in the state of
145
California.
Further, three billion dollars over a period of ten years
will be made available to fund and provide infrastructure for stem cell
138. Id.
139. Terri Somers, Stem Cell Research no Dream for California, SignOnSanDiego
(2006),
http://www.signonsandiego.com/news/business/biotech/20061219-9999-1z1n19stem.
html.
140. American Association for the Advancement of Science Policy Brief: Stem Cell
Research, Stem Cells in the States, available at http://www.aaas.org/spp/cstc/briefs/stemcells
(last visited Aug. 31, 2007).
141. The NIH spent $29 million in 2003 for stem cell research in the entire nation.
Gulbrandsen, supra note 125.
142. Pollack, supra note 2.
143. President Discusses Stem Cell Research, The White House, Aug. 9, 2001,
available at http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html (last visited
Aug. 31, 2007).
144. Proposition 71 was codified as CAL. CONST. art. XXXV. California Stem Cell
Research and Cures Initiative, Prop. 71, 2004 Cal. Text of Proposed Laws, available at
http://www.cirm.ca.gov/pdf/prop71.pdf.
145. Id.
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research.
This outstanding commitment to the advancement of
science is unique in terms of magnitude and structure. California is the
147
“first state to publicly fund embryonic stem cell research.”
It is thus not surprising that California has a strong interest in the
availability of stem cell technology. However, while this strong interest
is understandable and even honorable, the validity of a patent is not
dependent on state interests. The FTCR alleges that the “patents could
148
The
impede th[e] state’s $3 billion stem cell research program.”
opposite is true, however, because the patents make many aspects of
this program possible. Without the patents, the technology would not
be in the hands of scientists outside of Geron and the Thomson
laboratory. Instead, the technology would be a strictly guarded trade
secret in the hands of Geron who paid for research, and neither
academia nor industry would have access to it. Surely, scientists would
be free to try to generate their own stem cells in the absence of a patent.
However, before Dr. Thomson’s success, scientists have failed for
149
decades to do so. Thus, the patents under reexamination make many
aspects of human stem cell research possible, rather than hindering it.
I. Scientists Are Not Moving Abroad to Conduct Their Research
Opponents to the stem cell patents have argued that scientists
150
interested in working in the stem cell field will flee to other countries.
While this argument sounds plausible, it has not been corroborated by
any sound statistical analysis.
Quite the opposite is true. There are over 5,000 federally funded
current or past stem cell-related research projects in the United
151
States.
Furthermore, there are numerous private and public
companies, not included in this number, that have “taken a good look at
152
stem-cell research.”
In fact, the stem cell research “field is cluttered

146. Id.
147. Richard Guerra, States Take the Initiative to Regulate And Resolve the Stem Cell
Debate, 7 FL. COASTAL L. REV. 35, 46 (2005).
148. Pollack, supra note 42.
149. See Wei et al., supra note 67, at 167.
150. Press Release, Foundation for Taxpayer and Consumer Rights, Groups Challenge
Stem Cell Patents That Loot Taxpayer Funds and Force Research Overseas (July 18, 2006),
available at http://www.consumerwatchdog.org/pr/?postId=6572 (last visited Sept. 23, 2007).
151. http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen (last visited Aug. 31,
2007).
152. Matthew Herper, Stock Focus: Stem-Cell Companies, FORBES, Aug. 3, 2001,
available at http://www.forbes.com/2001/08/03/0803sf.html.
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153

with companies.” Thus, it can hardly be said that the stem cell patents
force U.S. research endeavors and stem cell scientists abroad.
There may be several reasons why U.S. stem cell scientists are
unlikely to go abroad to conduct their research. The most obvious one
is that individuals are more likely to switch their research focus than
leave their country. It is a great personal commitment and requires
great courage to leave behind your home and endeavor into the
unknown. Many are not willing to adapt into foreign cultures, learn new
languages, and leave their roots, just to work in a particular area of
science. Second, foreign countries have granted several stem cell
154
Further, some countries do not permit any stem cell
patents.
155
research.
Thus, U.S. scientists are unlikely to move their operations
abroad because the technology is either patented or prohibited. Third,
it is not clear if U.S. scientists’ work abroad will be favorably reviewed
in the United States. In other words, scientists that are hoping to
establish themselves in the scientific community and move up within a
U.S. institution may not be able to accomplish this goal with research
conducted abroad. Finally, not all countries that would provide for
equivalent research facilities permit unbridled embryonic stem cell
156
Thus, the argument that the WARF patents drive U.S.
research.
scientists to move abroad is unlikely to be meaningful. While there
might be individual examples, there is no empirical evidence to support
this argument and there is not likely to be any in the future. It might be
added that even if there was “stem cell off shoring,” it is due to “the
2001 order by President Bush that restricts federal funding here to
157
research on a small number of embryonic stem cell lines.”
CONCLUSION
The stem cell patents currently under reexamination by the USPTO
should be upheld. WARF’s patents are not obvious in light of the newly

153. Id.
154. See, e.g., Matt Wilkinson, ReNeuron Awarded EU Stem Cell Patents, Drug
Researcher, Apr. 4, 2007, http://www.drugresearcher.com/news/printNewsBis.asp?id=75830.
155. Human embryonic stem cell research is permitted in Belgium, Britain, Denmark,
Finland, Greece, the Netherlands, and Sweden, but not permitted in Austria, Germany,
Ireland, Italy and Portugal. See, e.g., Wikipedia, Stem Cell Research Policy, http://en.wiki
pedia.org/wiki/Stem_cell_research_policy (last visited Aug. 31, 2007).
156. E.g., Germany enacted the Embryoneschutzgesetz in 1990, EschG, BG1. L 2001,
S. 2702.
157. Tom Still, Here’s why Wisconsin’s Stem Cell Patents are Being Challenged, WIS.
TECH. NETWORK (Apr. 18, 2007), http://wistechnology.com/printarticle.php?id=3857.
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cited prior art. In addition, in times where embryonic research is largely
dependent on private investors, it is especially important to provide for
reliable protection of intellectual property. WARF has shared the
patented technology extensively with the scientific community and will
continue to do so. The fact that commercial entities cannot use the
patented technologies to maximize their company’s wealth is not
sufficient to hold the patents invalid.
Importantly, the patent system ought to provide a sense of stability
that withstands any political winds. It is currently challenging for
competitors to design around the stem cell patents due to the
restrictions on the generation of new lines. However, patents should be
inert against any changes in the political climate. Otherwise, a patent’s
term would be effectively reduced to the term of government.
Patents ensure that the protected technology is used to its fullest.
Scientific research is moved by “trends” that temporarily make a
technology “de joure” popular for use by researchers in different
158
fields. Once the next trend comes along, all interest is focused on this
new technology. The investment in a patent assures that a technique, if
it is promising, will be developed and exploited to its fullest. Stem cell
research bears enormous promise. This technology must be protected
to ensure investment of time, money, and effort to ensure its
development to the fullest possible benefit to mankind.
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